Reset Pharma is developing psilocybin-inspired therapies that aim to reset neural networks in patients facing demoralization due to life-threatening diseases like cancer. By leveraging neuro-biotechnology, the company seeks to enhance the quality of life for terminal patients through targeted mental health interventions.
Funding
$11.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients facing life-threatening diseases such as cancer often experience demoralization syndrome, a psychological trauma that significantly diminishes their quality of life. Current treatments may not adequately address the underlying neural network dysfunction associated with this condition.
Solution
Reset Pharma is developing psilocybin-inspired therapies designed to reset neural networks in the brain and reconnect individuals to meaning in their lives. These first-in-class therapies aim to move patients beyond the psychological trauma associated with life-altering diagnoses. By targeting the neurobiological underpinnings of demoralization, Reset Pharma seeks to improve mental health outcomes and enhance the overall well-being of patients facing severe illness. The company collaborates with leading research institutions and leverages neuro-biotechnology to bring its treatment to market.
Target Audience
The primary target audience includes patients diagnosed with life-threatening diseases, such as cancer, who are experiencing demoralization syndrome, as well as the healthcare providers who treat them.
Features
- Psilocybin-inspired compounds with potential to modulate neural network activity
- Targeted interventions for demoralization syndrome associated with life-threatening diseases
- Collaboration with leading research institutions, including a worldwide license from NYU
- Focus on improving mental health and reconnecting patients to meaning in their lives